BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 30645134)

  • 1. Effect of Polymer Hydrophobicity on the Stability of Amorphous Solid Dispersions and Supersaturated Solutions of a Hydrophobic Pharmaceutical.
    Frank DS; Matzger AJ
    Mol Pharm; 2019 Feb; 16(2):682-688. PubMed ID: 30645134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the Interplay between Amorphous Solid Dispersion Stability and Polymer Functionality.
    Frank DS; Matzger AJ
    Mol Pharm; 2018 Jul; 15(7):2714-2720. PubMed ID: 29924614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
    Baghel S; Cathcart H; O'Reilly NJ
    J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mid-infrared spectroscopy as a polymer selection tool for formulating amorphous solid dispersions.
    Wegiel LA; Mauer LJ; Edgar KJ; Taylor LS
    J Pharm Pharmacol; 2014 Feb; 66(2):244-55. PubMed ID: 24433425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular Mechanism, Microstructure, and Its Impact on Dissolution Performance.
    Chen H; Pui Y; Liu C; Chen Z; Su CC; Hageman M; Hussain M; Haskell R; Stefanski K; Foster K; Gudmundsson O; Qian F
    J Pharm Sci; 2018 Jan; 107(1):317-326. PubMed ID: 29107047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solubility advantage from amorphous etoricoxib solid dispersions.
    Dani P; Puri V; Bansal AK
    Drug Dev Ind Pharm; 2014 Jan; 40(1):92-101. PubMed ID: 23301771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System.
    Baghel S; Cathcart H; O'Reilly NJ
    Mol Pharm; 2018 Sep; 15(9):3796-3812. PubMed ID: 30020788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: combination of polymers showing drug-polymer interaction for synergistic effects.
    Prasad D; Chauhan H; Atef E
    J Pharm Sci; 2014 Nov; 103(11):3511-3523. PubMed ID: 25196860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Behavior of Resveratrol Solid Dispersions Upon Addition to Aqueous media.
    Wegiel LA; Mosquera-Giraldo LI; Mauer LJ; Edgar KJ; Taylor LS
    Pharm Res; 2015 Oct; 32(10):3324-37. PubMed ID: 25975588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Polymer Enrichment at the Crystal-Liquid Interface on Crystallization Kinetics of Amorphous Solid Dispersions.
    Zhang J; Shi Q; Tao J; Peng Y; Cai T
    Mol Pharm; 2019 Mar; 16(3):1385-1396. PubMed ID: 30716277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture.
    Rumondor AC; Marsac PJ; Stanford LA; Taylor LS
    Mol Pharm; 2009; 6(5):1492-505. PubMed ID: 19634917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations.
    Xie T; Taylor LS
    Pharm Res; 2016 Mar; 33(3):739-50. PubMed ID: 26563205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of polymer type and storage relative humidity on the kinetics of felodipine crystallization from amorphous solid dispersions.
    Rumondor AC; Stanford LA; Taylor LS
    Pharm Res; 2009 Dec; 26(12):2599-606. PubMed ID: 19806435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications.
    Qian F; Wang J; Hartley R; Tao J; Haddadin R; Mathias N; Hussain M
    Pharm Res; 2012 Oct; 29(10):2765-76. PubMed ID: 22315020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hydrophilic additives on the dissolution and pharmacokinetic properties of itraconazole-enteric polymer hot-melt extruded amorphous solid dispersions.
    Lang B; Liu S; McGinity JW; Williams RO
    Drug Dev Ind Pharm; 2016; 42(3):429-45. PubMed ID: 26355819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of drug-polymer solubility from supersaturated spray-dried amorphous solid dispersions: A case study with Efavirenz and Soluplus®.
    Costa BLA; Sauceau M; Del Confetto S; Sescousse R; Ré MI
    Eur J Pharm Biopharm; 2019 Sep; 142():300-306. PubMed ID: 31247317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage-Impact of different polymers.
    Wegiel LA; Mauer LJ; Edgar KJ; Taylor LS
    J Pharm Sci; 2013 Jan; 102(1):171-84. PubMed ID: 23132686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine.
    Konno H; Handa T; Alonzo DE; Taylor LS
    Eur J Pharm Biopharm; 2008 Oct; 70(2):493-9. PubMed ID: 18577451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular implications of drug-polymer solubility in understanding the destabilization of solid dispersions by milling.
    Yang Z; Nollenberger K; Albers J; Qi S
    Mol Pharm; 2014 Jul; 11(7):2453-65. PubMed ID: 24897345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation into Intermolecular Interactions and Phase Behavior of Binary and Ternary Amorphous Solid Dispersions of Ketoconazole.
    Sarpal K; Tower CW; Munson EJ
    Mol Pharm; 2020 Mar; 17(3):787-801. PubMed ID: 31860316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.